Close Menu

NEW YORK (GenomeWeb) – OpGen will meet with a Nasdaq panel in early 2018 to stave off being delisted from the exchange, the company said in a regulatory document on Tuesday.

In a Form 8-K filing with the US Securities and Exchange Commission, OpGen said that it received written notice on Dec. 21 from Nasdaq informing the company that the exchange would be delisting its stock on Jan. 2, 2018 if it did not request a hearing with a Nasdaq Hearing Panel in relation to the firm's failure to meet certain listing requirements.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.